[go: up one dir, main page]

WO2002078718A3 - Compositions, methods and apparatuses for singlet oxygen delivery - Google Patents

Compositions, methods and apparatuses for singlet oxygen delivery Download PDF

Info

Publication number
WO2002078718A3
WO2002078718A3 PCT/US2002/000513 US0200513W WO02078718A3 WO 2002078718 A3 WO2002078718 A3 WO 2002078718A3 US 0200513 W US0200513 W US 0200513W WO 02078718 A3 WO02078718 A3 WO 02078718A3
Authority
WO
WIPO (PCT)
Prior art keywords
singlet oxygen
methods
apparatuses
compositions
oxygen delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/000513
Other languages
French (fr)
Other versions
WO2002078718A2 (en
Inventor
Randolph M Howes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002435390A priority Critical patent/CA2435390A1/en
Priority to AU2002309477A priority patent/AU2002309477A1/en
Priority to JP2002576983A priority patent/JP2004524356A/en
Priority to EP02736475A priority patent/EP1353679A2/en
Publication of WO2002078718A2 publication Critical patent/WO2002078718A2/en
Publication of WO2002078718A3 publication Critical patent/WO2002078718A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods of treating tumors, lesions, and cancers comprising delivering to the affected site a combination of peroxide and hypochlorite anion. Hydrogen peroxide and sodium hypochlorite are possible sources of peroxide and hypochlorite anion, respectively. The reactants may be injected simultaneously or sequentially, and combine at the site to produce singlet oxygen. Singlet oxygen may be delivered to the treatment site or generated at the treatment site.
PCT/US2002/000513 2001-01-22 2002-01-18 Compositions, methods and apparatuses for singlet oxygen delivery Ceased WO2002078718A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002435390A CA2435390A1 (en) 2001-01-22 2002-01-18 Compositions, methods and apparatuses for singlet oxygen delivery
AU2002309477A AU2002309477A1 (en) 2001-01-22 2002-01-18 Compositions, methods and apparatuses for singlet oxygen delivery
JP2002576983A JP2004524356A (en) 2001-01-22 2002-01-18 Compositions, methods, devices and systems for singlet oxygen delivery
EP02736475A EP1353679A2 (en) 2001-01-22 2002-01-18 Compositions, methods and apparatuses for singlet oxygen delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26263501P 2001-01-22 2001-01-22
US60/262,635 2001-01-22

Publications (2)

Publication Number Publication Date
WO2002078718A2 WO2002078718A2 (en) 2002-10-10
WO2002078718A3 true WO2002078718A3 (en) 2003-05-30

Family

ID=22998355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000513 Ceased WO2002078718A2 (en) 2001-01-22 2002-01-18 Compositions, methods and apparatuses for singlet oxygen delivery

Country Status (5)

Country Link
EP (1) EP1353679A2 (en)
JP (1) JP2004524356A (en)
AU (1) AU2002309477A1 (en)
CA (1) CA2435390A1 (en)
WO (1) WO2002078718A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000341A1 (en) * 2003-06-25 2005-01-06 Vib Vzw Use of cytosolic phospholipid hydroperoxide glutathione peroxidase to reduce tumor growth
US20050281890A1 (en) * 2004-06-18 2005-12-22 San Chandan K Methods and compositions for wound healing
CN103432581A (en) * 2013-03-22 2013-12-11 北京海思威科技有限公司 Application of carbamide peroxide injection in inactivation of viruses for treating diseases
US10245129B2 (en) * 2013-06-07 2019-04-02 Panasonic Intellectual Property Management Co., Ltd. Tooth bleaching device
WO2023028251A1 (en) * 2021-08-25 2023-03-02 The Johns Hopkins University Endoscopic, percutaneous and other methods for dissolution of pancreatic necrosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4137544A1 (en) * 1991-11-12 1993-05-13 Hepper Martin Antimicrobial compsn. for antiseptic and disinfectant for skin - comprises cpds. yielding oxygen@ and chlorine@ quat. ammonium cpd., surfactant, aluminium chloride carbamide, urea, allantoin, panthenol and lactic acid
US5472715A (en) * 1992-12-11 1995-12-05 Japan Lotion Company Antifungal agent for the treatment of skin disease caused by trichophyton, eczema or various fungi, and also for activating the recovery of the skin and burns
US6033662A (en) * 1991-02-21 2000-03-07 Exoxemis, Inc. Oxygen activatable formulations for disinfection or sterilization
JP2000193653A (en) * 1998-12-28 2000-07-14 Seitai Hikari Joho Kenkyusho:Kk Erasing agent erasing ability judgment method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6033662A (en) * 1991-02-21 2000-03-07 Exoxemis, Inc. Oxygen activatable formulations for disinfection or sterilization
DE4137544A1 (en) * 1991-11-12 1993-05-13 Hepper Martin Antimicrobial compsn. for antiseptic and disinfectant for skin - comprises cpds. yielding oxygen@ and chlorine@ quat. ammonium cpd., surfactant, aluminium chloride carbamide, urea, allantoin, panthenol and lactic acid
US5472715A (en) * 1992-12-11 1995-12-05 Japan Lotion Company Antifungal agent for the treatment of skin disease caused by trichophyton, eczema or various fungi, and also for activating the recovery of the skin and burns
JP2000193653A (en) * 1998-12-28 2000-07-14 Seitai Hikari Joho Kenkyusho:Kk Erasing agent erasing ability judgment method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DI MASCIO PAOLO ET AL: "Singlet molecular oxygen production in the reaction of peroxynitrite with hydrogen peroxide.", FEBS LETTERS, vol. 355, no. 3, 1994, pages 287 - 289, XP002219249, ISSN: 0014-5793 *
FOOTE C S; WEXLER S: "Olefin Oxidations with Excited Singlet Molecular Oxygen", J AMER CHEM SOC, vol. 86, 1964, pages 3879 - 3880, XP002219248 *

Also Published As

Publication number Publication date
WO2002078718A2 (en) 2002-10-10
AU2002309477A1 (en) 2002-10-15
JP2004524356A (en) 2004-08-12
EP1353679A2 (en) 2003-10-22
CA2435390A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
WO2005016234A3 (en) Compositions, methods, apparatuses, and systems for singlet oxygen delivery
MXPA03007837A (en) Compositions for delivering bisphosphonates.
MXPA02012817A (en) Liposomal antineoplastic drugs and uses thereof.
NO20032759L (en) 2-phenylbenzimidazoles and imidazo [4,5] pyridines as Cds1 / Chk2 inhibitors and adjuvants for chemotherapy or radiation therapy in cancer treatment
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
GB2434983A (en) Methods and compositions for wound healing
WO1999043355A3 (en) Formulations containing oxaliplatin
MX2007002398A (en) New pharmaceutical compositions for the treatment of cancer.
EP2767291A3 (en) Treatment of glycogen storage disease type II
AU2003233287A1 (en) Compositions and methods for delivery of photosensitive drugs
WO2002102306A3 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
MXPA04003674A (en) Improved use of antitumoral compound in cancer therapy.
UA72927C2 (en) Docetaxel-containing composition for treating hepatocellular carcinoma
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
WO2002078718A3 (en) Compositions, methods and apparatuses for singlet oxygen delivery
MY130957A (en) Triazine derivatives and their application as antitelomerase agents
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
MXPA06007007A (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours.
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
MXPA04005942A (en) Syn3 compositions and methods.
MX2008001661A (en) Methods for treating b-cell malignancies using taci-ig fusion molecule.
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
EP1303300A4 (en) Compositions and methods for treatment of candidiasis
AU2003235791A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
IL159770A0 (en) Calcium salts with cytotoxic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2435390

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002736475

Country of ref document: EP

Ref document number: 2002576983

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002736475

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002736475

Country of ref document: EP